The combined power from Caris' DNA, RNA and imaging data with Flatiron's world-classclinical data establishes a powerful multimodal dataset to drive next-gen therapeutic development and advance patient careIRVING, Texas, Jan. 8, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, and Flatiron Health, a leading healthtech company transforming evidence generation through an engaged care network, oncology-specific expertise, and fit-for-purpose scientific methods and tools, today announced a partnership to create a multimodal data offering to support and accelerate biopharmaceutical drug development and patient care..

Caris的DNA、RNA和成像数据与Flatiron的世界一流临床数据的结合，建立了一个强大的多模式数据集，以推动下一代治疗发展和推进患者护理，德克萨斯州，2024年1月8日/PRNewswire/--Caris Life Sciences®（Caris），领先的下一代AI TechBio公司和精准医学先驱，正在积极开发和提供创新解决方案，以利用分子科学和AI彻底改变医疗保健并改善人类状况，而Flatiron Health是领先的healthtech公司，通过参与式护理网络，肿瘤学专业知识，以及适合目的的科学方法和工具，今天宣布建立合作伙伴关系，创建多模式数据，以支持和加速生物制药药物开发和患者护理。。

Continue Reading

继续阅读

Combining the breadth and depth of Caris' genomic, transcriptomic and imaging database with Flatiron's industry-leading longitudinal patient data and high-quality clinical outcomes, backed by deep scientific expertise, equips cancer researchers with robust comprehensive real-world data (RWD) offering at scale to power the next wave of cancer therapeutics..

将Caris基因组、转录组和成像数据库的广度和深度与Flatiron业界领先的纵向患者数据和高质量的临床结果相结合，再加上深厚的科学专业知识，为癌症研究人员提供强大的综合现实世界数据（RWD），为下一波癌症治疗提供大规模的支持。。

We can provide this incredibly powerful data at a scale that will fuel drug discovery and therapeutic innovation

我们可以提供这种难以置信的强大数据，其规模将推动药物发现和治疗创新

Post this

发布此

'We are excited to collaborate with Flatiron Health to create a multimodal data offering in support of biopharma's efforts to bring novel personalized therapeutic interventions to market to ultimately improve the lives of cancer patients,' said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences.

Caris Life Sciences总裁David Spetzler女士、博士、MBA说：“我们很高兴与Flatiron Health合作，创建一个多模式数据，支持生物制药公司将新型个性化治疗干预措施推向市场，最终改善癌症患者的生活。”。

'In forming this data union, we are able to maximize biological and clinical context to better understand each patient journey.' .

“通过建立这个数据联盟，我们能够最大限度地利用生物学和临床背景，更好地了解每个患者的旅程。”。

'We are thrilled to announce this groundbreaking partnership that brings together Caris' leading molecular science capabilities with Flatiron's unparalleled gold standard of high-quality oncology real-world data,' said Stephanie Reisinger, Senior Vice President and General Manager, Real-World Evidence, Flatiron Health.

Flatiron Health高级副总裁兼真实世界证据总经理斯蒂芬妮·赖辛格（StephanieReisinger）说：“我们很高兴宣布这一开创性的合作伙伴关系，它将Caris领先的分子科学能力与Flatiron无与伦比的高质量肿瘤学真实世界数据黄金标准结合在一起。”。

'This opportunity has the potential to create the largest and best-in-class clinical-omics dataset with Whole Exome and Whole Transcriptome sequencing coverage, expanding our opportunity to support biopharma in the preclinical stages of drug discovery and translation.''Identifying sufficient numbers of records to build cohorts of adequate size that can be used to address the most pressing research questions is a challenge that plagues the oncology community. With Caris and Flatiron's combined strength and broad reach across oncology, we can provide this incredibly powerful data at a scale that will fuel drug discovery and therapeutic innovation,' said Brian Lamon, PhD, Chief Business Officer of Caris Life Sciences.As the pioneer in precision medicine and molecular profiling, Caris has created a molecular-rich, real-world database that contains more than 50 petabytes of oncology-specific genomic, transcriptomic, proteomic and imaging data.

“这一机会有可能创建具有全外显子组和全转录组测序覆盖率的最大和最好的临床组学数据集，扩大我们在药物发现和翻译的临床前阶段支持生物制药的机会。”确定足够数量的记录以建立足够规模的队列，以解决最紧迫的研究问题，这是困扰肿瘤学界的一项挑战。Caris Life Sciences首席商务官布莱恩·拉蒙（BrianLamon）博士说，凭借Caris和Flatiron的综合实力和在肿瘤学领域的广泛影响力，我们可以提供这些难以置信的强大数据，从而推动药物发现和治疗创新。作为精准医学和分子分析的先驱，Caris创建了一个分子丰富的现实世界数据库，其中包含超过50 PB的肿瘤特异性基因组，转录组，蛋白质组和成像数据。

Caris was the first in the molecular diagnostic industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA coverage (WES / WTS) for every patient tested.About Caris Life SciencesCaris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI.

Caris是分子诊断行业中第一个为每位接受测试的患者提供全外显子组测序DNA覆盖率和全转录组测序RNA覆盖率（WES/WTS）的公司。关于Caris生命科学Caris Life Sciences®（Caris）是领先的下一代AI TechBio公司和精准医学先驱，正在积极开发和提供创新解决方案，以利用分子科学和AI彻底改变医疗保健并改善人类状况。

Through comprehensive molecular profiling (Who.

通过全面的分子谱分析（Who）。